arrow_back Back to App

Drug Supply Security: Facilitating Pharmaceutical Trade and Production

This act aims to enhance the security of drug supplies, especially during emergencies, by facilitating international trade and pharmaceutical production. Citizens can expect greater availability of medicines and more stable prices due to streamlined regulatory processes and international cooperation. These changes are intended to reduce the risk of drug shortages in the market.
Key points
Easier Drug Trade: Reducing or eliminating tariffs and regulatory barriers on drug imports, especially in emergencies.
Support for Drug Production: Promoting faster approval of manufacturing facilities and processes, and encouraging investment in pharmaceutical production.
Increased Transparency and Cooperation: Information sharing among countries to prevent supply chain issues and coordinate actions in the pharmaceutical sector.
Extension of Trade Agreement Authority: The U.S. government gains more time to negotiate new trade agreements, which may impact future drug import and export conditions.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_4711
Sponsor: Rep. Joyce, John [R-PA-13]
Process start date: 2021-07-27
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

International Pharmaceutical Supply Chain Security Agreement Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_4711.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-07-27.

What are the main provisions?

Key points include:

  • Easier Drug Trade: Reducing or eliminating tariffs and regulatory barriers on drug imports, especially in emergencies.
  • Support for Drug Production: Promoting faster approval of manufacturing facilities and processes, and encouraging investment in pharmaceutical production.
  • Increased Transparency and Cooperation: Information sharing among countries to prevent supply chain issues and coordinate actions in the pharmaceutical sector.
  • Extension of Trade Agreement Authority: The U.S. government gains more time to negotiate new trade agreements, which may impact future drug import and export conditions.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Joyce, John [R-PA-13].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Trade.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

CATEGORIES

Health Economy